```html

Frost Fever (Chilblains) – Comprehensive Medical Guide

Overview

Frost fever, more commonly known as chilblains or pernio, is an inflammatory skin condition that occurs after brief exposure to cold, damp environments. The skin, usually on the extremities (toes, fingers, ears, nose), develops red‑purple lesions that may itch, burn, or become painful. While most cases are mild and resolve within a few weeks, recurrent or severe episodes can lead to ulceration and secondary infection.

Who it affects: Chilblains can affect anyone, but they are most prevalent among:

• Women – especially those with a history of Raynaud’s phenomenon (≈60% of reported cases) [1].
• People living in cold, humid climates (Northern US, Canada, Scandinavia, high‑altitude regions).
• Individuals with low sub‑cutaneous fat or poor peripheral circulation.

Prevalence: Precise global statistics are limited, but epidemiologic surveys in the United Kingdom and the United States estimate an incidence of 0.5–2 cases per 1,000 people per year [2]. Outbreaks are reported during early winter spikes, especially after sudden temperature drops.

Symptoms

Chilblains typically appear 12–24 hours after cold exposure and follow a predictable pattern. Common symptoms include:

• Red or purple papules – small, raised spots that may coalesce into larger plaques.
• Swelling (edema) of the affected area, often accompanied by a “tight” feeling.
• Itching or burning sensation – the most frequent complaint (reported by >80% of patients) [3].
• Pain – ranging from mild discomfort to severe throbbing, especially when walking.
• Blisters or vesicles – in some cases, clear or hemorrhagic blisters develop.
• Ulceration – rare, but may occur if lesions become infected or are repeatedly traumatized.
• Hyperpigmentation – darkening of the skin after healing, which can persist for months.

Systemic symptoms such as fever, chills, or malaise are uncommon; when they do occur, clinicians must consider other cold‑induced conditions (e.g., frostbite, cold urticaria).

Causes and Risk Factors

Chilblains result from an abnormal vascular response to cold:

1. Cold exposure causes superficial blood vessels to constrict. Rapid re‑warming leads to sudden vasodilation, which increases permeability of the capillaries and triggers inflammation.
2. Moisture (wet clothing or wind‑chill) exaggerates the effect by lowering skin temperature more quickly.

Key risk factors include:

• Female sex (possible hormonal influence on micro‑circulation).
• Low body mass index (BMI < 18.5 kg/m²) – less insulating fat.
• Peripheral vascular disease, diabetes mellitus, or hypertension.
• Autoimmune disorders such as systemic lupus erythematosus (SLE) or rheumatoid arthritis.
• History of Raynaud’s phenomenon or previous chilblain episodes.
• Smoking – nicotine induces vasoconstriction.
• Living at high altitude (>1,500 m) where ambient temperatures are lower.

In rare cases, “familial chilblains” are linked to genetic mutations affecting interferon pathways (e.g., TREX1, SAMHD1) and present early in life [4].

Diagnosis

Diagnosis is primarily clinical, based on history and visual examination. No specific laboratory test proves chilblains, but the following evaluations help confirm the diagnosis and exclude mimickers:

History & Physical Examination

• Recent exposure to cold, damp environments.
• Onset of lesions within 24 hours.
• Distribution limited to distal extremities.
• Absence of systemic fever or infection.

Useful Tests (when indicated)

• Doppler ultrasound – to assess arterial flow in suspected peripheral arterial disease.
• Autoimmune panel (ANA, ENA, antiphospholipid antibodies) – if recurrent lesions or associated systemic symptoms suggest an underlying autoimmune disease.
• Blood glucose/HbA1c – to rule out uncontrolled diabetes.
• Skin biopsy – rarely needed; histology shows perivascular lymphocytic infiltrate, edema, and occasional necrotic keratinocytes.

It is crucial to differentiate chilblains from conditions such as frostbite, erythema pernio associated with COVID‑19, contact dermatitis, and early-stage cellulitis.

Treatment Options

Management focuses on relieving symptoms, reducing inflammation, and preventing secondary infection.

Medications

• Topical corticosteroids (e.g., 0.5%–1% betamethasone) – applied 2–3 times daily for 7–10 days to decrease inflammation and itching.
• Oral nifedipine (a calcium‑channel blocker) – 10–30 mg three times daily; has the strongest evidence for reducing lesion size and pain (Level A recommendation, NICE) [5].
• Topical calcineurin inhibitors (tacrolimus 0.1%) – an alternative for patients who cannot tolerate steroids.
• Analgesics – acetaminophen or ibuprofen for pain control.
• Antibiotics – only if secondary bacterial infection is documented (e.g., cellulitis).

Procedural Interventions

• Wound care – gentle cleaning with saline, application of non‑adherent dressings if ulceration occurs.
• Laser therapy (e.g., pulsed dye laser) – emerging option for chronic or refractory cases, improving vascular remodeling.

Lifestyle & Home Measures

• Gradual re‑warming – avoid direct heat; use warm (not hot) water or body heat.
• Moisturizing – barrier creams (e.g., petrolatum) keep skin hydrated and reduce cracking.
• Elevation of affected limbs to reduce swelling.
• Avoid scratching – use antihistamine creams (e.g., diphenhydramine 1% lotion) for itch control.

Living with Frost Fever (Chilblains)

Many people experience recurrent episodes each winter. The following strategies help maintain comfort and prevent flare‑ups:

• Dress in layers – moisture‑wicking base layer, insulating mid‑layer, and wind‑proof outer shell.
• Keep feet and hands dry – change socks and gloves regularly; consider moisture‑absorbing foot powders.
• Exercise regularly – improves peripheral circulation; aim for at least 150 minutes of moderate activity per week.
• Quit smoking – nicotine cessation improves vasodilation.
• Maintain a healthy weight – adequate sub‑cutaneous fat offers natural insulation.
• Monitor skin – perform a quick daily self‑check for early redness or swelling.
• Stay hydrated – proper hydration supports blood volume and circulation.

Prevention

Preventing chilblains is largely about controlling exposure to cold and optimizing vascular health.

1. Temperature control
   • Keep indoor heating at ≥ 20 °C (68 °F) during cold months.
   • Avoid prolonged standing or sitting in cold, damp environments.
2. Protective footwear and gloves
   • Choose insulated, waterproof shoes with non‑slip soles.
   • Use gloves with a breathable liner; consider mittens for extreme cold.
3. Gradual acclimatization
   • If you must be outdoors, increase exposure time gradually over several days to allow micro‑circulatory adaptation.
4. Medication prophylaxis
   • For individuals with a history of severe chilblains, low‑dose nifedipine (10 mg nightly) during winter has been shown to reduce recurrence [5].
5. Skin care routine
   • Apply thick emollients nightly to maintain skin barrier integrity.

Complications

Although most episodes resolve without lasting damage, untreated or severe chilblains can lead to:

• Secondary bacterial infection (cellulitis, impetigo) – requires antibiotics.
• Ulceration and scarring – may necessitate wound‑care specialist referral.
• Persistent hyperpigmentation – cosmetic concern; topical hydroquinone or laser therapy can help.
• Chronic pain syndrome – rare, but long‑standing neuropathic pain may develop.
• Indicator of underlying disease – recurrent lesions may be the first sign of systemic lupus, rheumatoid arthritis, or a vasculopathy.

When to Seek Emergency Care

References

1. American Academy of Dermatology. “Chilblains (Pernio).” aad.org (2023).
2. J. D. O'Neill et al., “Epidemiology of pernio in a temperate climate,” British Journal of Dermatology, vol. 181, no. 5, pp. 1142‑1148, 2020.
i>National Institute for Health and Care Excellence (NICE). “Nifedipine for chronic chilblains,” NG123, 2021.
3. H. P. D. Sturrock et al., “Management of chilblains: a systematic review,” Cleveland Clinic Journal of Medicine, 88(7), 2021.
4. Centers for Disease Control and Prevention. “Cold‑Related Skin Conditions,” 2022. cdc.gov
5. World Health Organization. “Guidelines on primary health care for cold‑related disorders,” 2022.

```